Connect Biopharma (CNTB) Competitors $1.09 -0.05 (-4.08%) Closing price 03:59 PM EasternExtended Trading$1.12 +0.04 (+3.25%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTB vs. PRQR, NBTX, YMAB, IMAB, CRDF, INBX, MDWD, SOPH, MNPR, and SCPHShould you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include ProQR Therapeutics (PRQR), Nanobiotix (NBTX), Y-mAbs Therapeutics (YMAB), I-Mab (IMAB), Cardiff Oncology (CRDF), Inhibrx Biosciences (INBX), MediWound (MDWD), SOPHiA GENETICS (SOPH), Monopar Therapeutics (MNPR), and scPharmaceuticals (SCPH). These companies are all part of the "pharmaceutical products" industry. Connect Biopharma vs. Its Competitors ProQR Therapeutics Nanobiotix Y-mAbs Therapeutics I-Mab Cardiff Oncology Inhibrx Biosciences MediWound SOPHiA GENETICS Monopar Therapeutics scPharmaceuticals Connect Biopharma (NASDAQ:CNTB) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability. Which has stronger valuation and earnings, CNTB or PRQR? Connect Biopharma has higher revenue and earnings than ProQR Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConnect Biopharma$26.03M2.32-$15.63MN/AN/AProQR Therapeutics$20.46M11.83-$30.04M-$0.35-6.57 Which has more volatility & risk, CNTB or PRQR? Connect Biopharma has a beta of -0.2, meaning that its stock price is 120% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Do institutionals & insiders believe in CNTB or PRQR? 58.7% of Connect Biopharma shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is CNTB or PRQR more profitable? Connect Biopharma has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -157.04%. Connect Biopharma's return on equity of 0.00% beat ProQR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Connect BiopharmaN/A N/A N/A ProQR Therapeutics -157.04%-53.49%-22.07% Do analysts rate CNTB or PRQR? Connect Biopharma currently has a consensus price target of $7.00, suggesting a potential upside of 543.03%. ProQR Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 247.83%. Given Connect Biopharma's higher possible upside, analysts plainly believe Connect Biopharma is more favorable than ProQR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Connect Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the media prefer CNTB or PRQR? In the previous week, ProQR Therapeutics had 1 more articles in the media than Connect Biopharma. MarketBeat recorded 4 mentions for ProQR Therapeutics and 3 mentions for Connect Biopharma. ProQR Therapeutics' average media sentiment score of 0.22 beat Connect Biopharma's score of -0.30 indicating that ProQR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Connect Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryConnect Biopharma beats ProQR Therapeutics on 8 of the 15 factors compared between the two stocks. Get Connect Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTB vs. The Competition Export to ExcelMetricConnect BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$63.06M$2.90B$5.51B$8.96BDividend YieldN/A2.44%5.25%4.02%P/E RatioN/A21.0128.0520.15Price / Sales2.32294.68438.14127.85Price / CashN/A41.8337.0657.97Price / Book0.657.868.125.62Net Income-$15.63M-$54.95M$3.16B$248.50M7 Day Performance0.80%6.24%4.40%5.54%1 Month Performance39.39%5.70%4.09%7.52%1 Year Performance-16.26%8.08%34.53%22.06% Connect Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTBConnect Biopharma3.3157 of 5 stars$1.09-4.1%$7.00+543.0%-12.7%$63.06M$26.03M0.00110News CoverageHigh Trading VolumePRQRProQR Therapeutics2.1226 of 5 stars$2.04flat$8.00+292.2%+32.5%$214.63M$20.46M-5.83180News CoverageNBTXNanobiotix2.2463 of 5 stars$4.73+4.4%$8.00+69.1%+2.5%$213.34M$39.18M0.00100News CoveragePositive NewsGap UpYMABY-mAbs Therapeutics3.2647 of 5 stars$4.51-4.0%$15.60+245.9%-62.7%$212.83M$87.68M-7.05150IMABI-Mab2.8948 of 5 stars$2.42-5.8%$6.00+147.9%+41.0%$209.87M$3.89M0.00380News CoverageAnalyst ForecastGap UpCRDFCardiff Oncology1.6636 of 5 stars$3.15flat$9.88+213.5%+77.5%$209.56M$680K-3.4220News CoverageAnalyst ForecastINBXInhibrx Biosciences1.7924 of 5 stars$14.27-1.1%N/A+46.5%$208.89M$200K0.12166News CoverageMDWDMediWound1.6096 of 5 stars$19.37+0.6%$31.80+64.2%+0.1%$208.16M$20.22M-9.2780SOPHSOPHiA GENETICS2.3769 of 5 stars$3.10+0.3%$7.00+125.8%-21.2%$206.06M$65.17M-3.10520News CoverageMNPRMonopar Therapeutics2.9596 of 5 stars$35.78+6.5%$56.50+57.9%+940.0%$205.47MN/A-10.2810News CoverageAnalyst ForecastAnalyst RevisionGap UpSCPHscPharmaceuticals4.14 of 5 stars$3.81-1.6%$14.00+267.5%-9.4%$204.30M$36.33M-1.9930 Related Companies and Tools Related Companies PRQR Competitors NBTX Competitors YMAB Competitors IMAB Competitors CRDF Competitors INBX Competitors MDWD Competitors SOPH Competitors MNPR Competitors SCPH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTB) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
